Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Patients and clinicians urge regulated access to therapeutic psilocybin with equity protections
Summary
Patients, clinicians and advocates told the committee that regulated therapeutic psilocybin treatment centers (H2532) could offer a new tool for treatment‑resistant mental health conditions, but they cautioned that programs must be affordable and equitable to avoid creating a two‑tiered system.
Patients, clinicians and advocates spoke in support of H2532 to create a regulated framework for therapeutic psilocybin treatment centers, saying clinical trials and patient experience point to benefits for treatment‑resistant depression, PTSD and other conditions.
Graham Moore, a patient and caregiver and lead educator with the…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
